Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avalglucosidase alfa - Sanofi

Next Previous
X
Search
Drug Profile

Avalglucosidase alfa - Sanofi

Alternative Names: Avalglucosidase alfa-ngpt; GZ 402666; neo rhGAA; Neo-recombinant human acid alpha-glucosidase; Neo-rhGAA; Neo-rhGAA enzyme therapy; NeoGAA; Nexviadyme; Nexviazyme

Latest Information Update: 23 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi; Sanofi Genzyme
  • Class Alpha-glucosidases; Recombinant proteins
  • Mechanism of Action Alpha-glucosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glycogen storage disease type II
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glycogen storage disease type II

Most Recent Events

  • 06 Feb 2024 Adverse events data from a phase-III Baby-COMET trial in Glycogen storage disease type II released by Sanofi
  • 06 Feb 2024 Efficacy data from phase II mini-COMET trial in Glycogen storage disease type II released by Sanofi
  • 06 Feb 2024 Efficacy data from the phase II/III NEO-EXT trial in Glycogen storage disease type II released by Sanofi

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top